[Toward Personalized Cancer Therapy with Oral Molecular-targeted Agents]

Area of Science:

• Oncology
• Pharmacology
• Clinical Medicine

Background:

• Oral molecular-targeted agents are crucial for cancer treatment but can cause severe side effects or lack efficacy.
• Therapeutic drug monitoring (TDM) is increasingly studied to personalize these treatments and improve patient outcomes.
• While TDM for imatinib and sunitinib is insured in Japan, other tyrosine kinase inhibitors lack this coverage despite potential severe side effects.

Purpose of the Study:

• To establish a safe and effective chemotherapy regimen for Japanese cancer patients using scientific evidence.
• To investigate the correlation between plasma drug concentrations and clinical outcomes, including side effects and therapeutic effects.
• To present findings from renal cell carcinoma patient treatment at our institution.

Main Methods:

• Retrospective analysis of clinical data from Japanese patients treated with oral molecular-targeted agents.
• Examination of the relationship between plasma drug concentrations and observed clinical findings (side effects, treatment efficacy).
• Focus on patients with renal cell carcinoma.

Main Results:

• Analysis revealed specific correlations between drug concentrations and patient outcomes.
• Identification of factors influencing treatment efficacy and side effect profiles.
• Data suggests potential for optimized dosing strategies based on TDM.

Conclusions:

• TDM is essential for optimizing oral molecular-targeted therapy in cancer patients.
• Personalized treatment regimens based on TDM can enhance safety and efficacy.
• Further research and broader insurance coverage for TDM are warranted, especially for tyrosine kinase inhibitors.